Form 4: Puma Biotech Director Sells Shares Under 10b5-1 Plan

Puma Biotechnology Director Michael Patrick Miller sold 20,000 shares of common stock for approximately $4.86 per share on November 11, 2025, under a Rule 10b5-1 plan.

Summary

• Director Michael Patrick Miller of PUMA BIOTECHNOLOGY, INC. (PBYI) reported the sale of 20,000 shares of common stock.
• The transaction occurred on November 11, 2025, at a weighted average price of $4.8614 per share.
• The shares were sold in multiple transactions with prices ranging from $4.82 to $4.97, inclusive.
• Following this transaction, Mr. Miller directly beneficially owns 54,000 shares of PBYI common stock.
• The sale was conducted pursuant to a Rule 10b5-1(c) trading plan, indicating a pre-arranged transaction.

Sentiment

Score: 5

Explanation: A director's sale of shares is generally viewed neutrally to slightly negative, but the disclosure of a Rule 10b5-1 plan mitigates concerns about opportunistic selling, suggesting a pre-planned liquidity event rather than a reaction to new negative information.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, which indicates a pre-scheduled sale and reduces concerns about opportunistic insider trading.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence by some investors, although this is mitigated by the plan's nature.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is specific to an insider transaction at Puma Biotechnology and does not provide broader industry context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders may interpret the director's sale as a neutral to slightly negative signal, though the Rule 10b5-1 plan provides context that the sale was pre-planned and not necessarily based on new, undisclosed information.

Key Dates

Recommendation

The filing reports a pre-planned sale by a director under a Rule 10b5-1 plan. While insider selling can sometimes be a negative signal, the existence of a 10b5-1 plan suggests a scheduled liquidity event rather than a reaction to new, undisclosed negative information. Without further context on the company's performance or other market factors, this single transaction does not provide sufficient grounds for a strong buy or sell recommendation, thus a 'hold' is appropriate.

Keywords

PBYI, Puma Biotechnology, insider trading, Form 4, stock sale, director, Michael Patrick Miller, common stock, 10b5-1 plan